Last updated: February 17, 2026

Meperidine and Atropine Sulfate is a combination drug product primarily used for pain management and the treatment of opioid withdrawal symptoms. Its patent portfolio, market performance, and future trajectory are shaped by generic competition, evolving clinical guidelines, and the development of alternative pain therapies.

What is the Patent Status of Meperidine and Atropine Sulfate?

The original patents covering Meperidine and Atropine Sulfate have long expired, allowing for the widespread availability of generic versions. This means that the primary exclusivity periods for the core composition of matter and formulation patents have concluded. However, ongoing patent filings related to new formulations, delivery systems, or specific therapeutic uses could exist.

Composition of Matter Patents: These patents, which protect the fundamental chemical structure of the active pharmaceutical ingredients (APIs), Meperidine (also known as Pethidine) and Atropine, expired decades ago. Meperidine was first synthesized in the late 1930s.
Formulation Patents: Patents covering specific formulations (e.g., injectable solutions, tablets) for Meperidine and Atropine Sulfate would have also expired. The standard injectable formulation is the most prevalent.
Method of Use Patents: While less common for such established drugs, patents could have existed or may be filed for novel uses or specific patient populations. The primary indication is pain relief.
Evergreening Attempts: Pharmaceutical companies may attempt to extend market exclusivity through secondary patents for new delivery mechanisms or combination therapies. For Meperidine and Atropine Sulfate, the focus has historically been on the established injectable form.

What are the Key Market Drivers for Meperidine and Atropine Sulfate?

The market for Meperidine and Atropine Sulfate is influenced by several factors, primarily its established role in certain clinical settings, the availability of generics, and the competitive landscape of analgesics.

Clinical Utility: Meperidine is an opioid analgesic. The addition of atropine, an anticholinergic agent, can help mitigate certain side effects of meperidine, such as smooth muscle spasms, and may contribute to its analgesic effect. It is often used in acute pain settings, particularly in emergency departments and for post-operative pain.
Generic Availability: The absence of patent protection has led to a highly competitive generic market. This results in significant price erosion and a market dominated by multiple manufacturers of bioequivalent products.
Competition from Other Opioids: Meperidine competes with a wide range of other opioid analgesics, including morphine, oxycodone, hydromorphone, and fentanyl. These alternatives often have different pharmacokinetic profiles, potency, and side effect profiles, leading to prescriber preference based on specific clinical scenarios.
Concerns Regarding Normeperidine Accumulation: A significant factor influencing its use is the potential for accumulation of its active metabolite, normeperidine. Normeperidine is renally excreted and can accumulate in patients with renal impairment, leading to CNS toxicity, including seizures. This has led to a decline in its use in certain patient populations and a preference for other opioids.
Evolving Pain Management Guidelines: Current pain management guidelines often favor opioids with a lower risk of normeperidine accumulation and toxicity, and those with more predictable pharmacokinetic profiles. This trend has gradually reduced Meperidine's market share in favor of other agents.
Opioid Stewardship Programs: The broader push for opioid stewardship and responsible prescribing practices encourages the judicious use of all opioids, including Meperidine.

What is the Financial Trajectory and Market Size of Meperidine and Atropine Sulfate?

The financial trajectory of Meperidine and Atropine Sulfate is characterized by a mature, genericized market with declining sales volumes due to increased competition and a shift towards alternative pain management strategies.

Market Size: Precise current market size figures for Meperidine and Atropine Sulfate (specifically the combination product) are difficult to isolate from broader opioid analgesic market data. However, its market share has been steadily decreasing. Analysts estimate the total U.S. generic injectable opioid market to be in the hundreds of millions of dollars annually. Meperidine and Atropine Sulfate would represent a small fraction of this, likely in the tens of millions of dollars.
Sales Trends: Historical sales data from IMS Health (now IQVIA) and other market research firms indicate a consistent decline in both prescription volume and revenue for Meperidine over the past decade. This trend is expected to continue.
Pricing: Due to the generic nature of the product, pricing is highly competitive. The average selling price (ASP) for Meperidine and Atropine Sulfate injections is significantly lower compared to branded analgesics or newer pain management therapies. Prices are typically negotiated between manufacturers and distributors, and influenced by government formularies and hospital purchasing agreements.
Key Manufacturers: Several generic pharmaceutical companies manufacture Meperidine and Atropine Sulfate. Major players in the injectable generic market include Fresenius Kabi, Hikma Pharmaceuticals, and Teva Pharmaceuticals. Competition among these manufacturers drives down prices.
Projected Growth: The market for Meperidine and Atropine Sulfate is projected to experience negative growth. The decline is attributable to:
- Increased availability of alternative opioid analgesics with improved safety profiles or different therapeutic advantages.
- Restrictions on opioid prescribing and the emphasis on non-opioid pain management modalities.
- Concerns regarding the neurotoxicity of normeperidine.
- The maturation of the drug in the market, with no significant new patent-protected innovations anticipated.

What are the Competitive and Regulatory Challenges?

Meperidine and Atropine Sulfate faces significant competitive and regulatory hurdles that impact its market viability.

Competition:
- Other Opioids: Morphine, hydromorphone, fentanyl, and oxycodone remain dominant in the opioid analgesic space. Many are available in various formulations and have extensive clinical data supporting their use.
- Non-Opioid Analgesics: The market is increasingly shifting towards non-opioid pain management, including NSAIDs, acetaminophen, gabapentinoids, and topical analgesics, especially for chronic pain.
- Novel Pain Therapies: Development of new analgesics targeting different pain pathways offers alternatives with potentially better efficacy and safety profiles.
Regulatory Environment:
- Opioid Prescribing Regulations: Federal and state governments have implemented stricter regulations on opioid prescribing, including prescription drug monitoring programs (PDMPs), opioid use disorder treatment mandates, and limitations on opioid quantities and durations.
- FDA Actions: The U.S. Food and Drug Administration (FDA) has been active in addressing the opioid crisis, leading to changes in labeling, warnings, and the promotion of safer prescribing practices for all opioid products. This scrutiny extends to older opioids like Meperidine.
- Controlled Substance Classification: Meperidine is a Schedule II controlled substance under the U.S. Controlled Substances Act, requiring strict prescribing and dispensing protocols.
- Risk Evaluation and Mitigation Strategies (REMS): While not always specific to Meperidine, REMS programs for opioids in general can impact prescribing patterns and patient access.

What are the Future Market Projections?

The future market for Meperidine and Atropine Sulfate is expected to be characterized by continued decline, with its use becoming increasingly niche and reserved for specific clinical scenarios where its unique (though debated) properties are deemed necessary and risks are manageable.

Declining Prescription Volumes: Expect a consistent year-over-year decrease in the number of prescriptions written for Meperidine and Atropine Sulfate.
Reduced Market Share: Its proportion of the overall analgesic market will continue to shrink.
Niche Indications: Its use may be confined to specific situations, such as:
- Adjunct in shivering control during hypothermia protocols.
- Management of certain types of post-operative pain where other agents are contraindicated or ineffective, provided renal function is closely monitored.
- Management of opioid withdrawal symptoms in specific protocols.
Limited R&D Investment: There is minimal incentive for significant research and development investment in new formulations or indications for Meperidine and Atropine Sulfate due to its generic status, established risks, and the availability of superior alternatives.
Supply Chain Stability: While its use is declining, it is likely to remain available from generic manufacturers as long as there is a consistent, albeit small, demand from healthcare providers for specific indications.

Key Takeaways

Meperidine and Atropine Sulfate operates in a mature, highly competitive generic market. Its patent exclusivity has long expired, leading to price erosion. Market drivers include its specific, though increasingly limited, clinical applications and its competition with a wide array of other analgesics. Concerns about normeperidine toxicity and evolving pain management guidelines contribute to a projected decline in prescription volumes and market share. Regulatory pressures on opioid prescribing further constrain its market trajectory. The future market is expected to be characterized by niche use in specific clinical settings rather than broad application.

Frequently Asked Questions

1. Are there any remaining patents for Meperidine and Atropine Sulfate that could impact market entry for new manufacturers?

No significant patents on the core composition of matter or standard formulations of Meperidine and Atropine Sulfate exist. This allows multiple generic manufacturers to produce and market the drug. While hypothetical patents for novel delivery systems or specific therapeutic uses could be filed, these are unlikely to significantly alter the current market dynamics for the established injectable product.

2. What are the primary reasons for the declining use of Meperidine and Atropine Sulfate?

The declining use is primarily driven by the accumulation of its neurotoxic metabolite, normeperidine, particularly in patients with impaired renal function. This concern, coupled with the availability of alternative opioid analgesics with more favorable pharmacokinetic profiles and safety data, and evolving pain management guidelines that favor non-opioid or opioid-sparing strategies, have led to a reduction in its prescribing frequency.

3. How does Meperidine and Atropine Sulfate compare in terms of efficacy and safety to other commonly used opioids like morphine or hydromorphone?

While Meperidine provides opioid analgesia, its efficacy is often considered comparable to morphine for many types of pain. However, its safety profile is less favorable due to the risks associated with normeperidine accumulation, which can cause CNS excitation, tremors, and seizures. Morphine and hydromorphone generally have better-characterized safety profiles and are metabolized differently, reducing the risk of severe neurotoxicity from metabolites.

4. What are the potential future niche applications for Meperidine and Atropine Sulfate?

Potential niche applications include its use as an adjunct in managing shivering during therapeutic hypothermia protocols, certain specific scenarios of acute pain where other opioids are contraindicated or ineffective and renal function is carefully monitored, and as a component in certain protocols for managing opioid withdrawal symptoms. These applications are limited and require careful clinical judgment regarding risk-benefit assessment.

5. What is the economic impact of the genericization of Meperidine and Atropine Sulfate on pharmaceutical companies?

For generic manufacturers, the economic impact is characterized by high-volume, low-margin sales. The market is competitive, and profitability is driven by efficient manufacturing, supply chain management, and securing contracts with major distributors and healthcare systems. For original innovators (if any were involved in early development), the economic phase has long passed due to patent expiry, and revenue generation from this specific product is minimal or non-existent.

Citations

[1] National Center for Biotechnology Information. (n.d.). Meperidine and atropine sulfate. PubChem Compound Summary for CID 4683. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Meperidine-and-atropine-sulfate [2] U.S. Food and Drug Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.fda.gov/regulatory-information/laws-enforced-fda/controlled-substances-act [3] American Society of Health-System Pharmacists. (n.d.). Meperidine and Atropine Sulfate Injection. ASHP Drug Information. (Subscription required for detailed access, but general information on availability and status is publicly searchable). [4] IQVIA. (Various Market Reports). Global Pharmaceutical Market Data and Analytics. (Proprietary data, general trends referenced). [5] U.S. Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from https://www.dea.gov/drug-scheduling

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	MEPERIDINE AND ATROPINE SULFATE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

MEPERIDINE AND ATROPINE SULFATE Drug Patent Profile

When do Meperidine And Atropine Sulfate patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for MEPERIDINE AND ATROPINE SULFATE

US Patents and Regulatory Information for MEPERIDINE AND ATROPINE SULFATE

MEPERIDINE AND ATROPINE SULFATE: PATENT LANDSCAPE AND MARKET PROJECTIONS